Falls · Older people living in the community (trials focusing on people recently discharged from hospital were not included)
Summary of findings: 3D (Tai Chi) exercise may leads to lower rate of falls (falls per person‐year) compared with control (e.g. usual activities) (low certainty).
1 finding from 1 review
Number of people who experienced one or more falls · Older people living in the community (trials focusing on people recently discharged from hospital were not included)
Summary of findings: 3D (Tai Chi) exercise leads to lower number of people who experienced one or more falls compared with control (e.g. usual activities) (high certainty).
1 finding from 1 review
Adverse events · Older people living in the community (trials focusing on people recently discharged from hospital were not included)
1 finding from 1 review
Completeness of reporting Proportion of items adequately reported, from 0.00 to 1.00, higher number indicates more complete reporting. · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Peer reviewer detection of errors Number of major errors identified, assessed by 2 researchers independently, from 0 to 9, higher number indicates better detection. · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Stakeholders' assessment of review quality (final score) Assessed by 2 editors independently using the RQI from 1 to 5 (average of the 2 ratings), higher scores indicate higher quality. · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Stakeholders' assessment of review quality (change score) Assessed using either:A) a 5‐point scale, change scores range from −4 to 4 (3 studies);B) a 5‐point scale, expressed by "slope of quality score change"(1 study); orC) the MQAI, from −144 to... · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Inter‐reviewer agreement (final score) Assessed using the average deviation between reviewers, from −4 to 0, higher scores indicate higher agreement. · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Inter‐reviewer agreement (change score) Assessed using the average score difference between reviewers, possible changes scores range from −9 to 9, higher scores indicate increased agreement. · peer reviewers
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Bibliometric scores · peer reviewers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms – improvement – medium term · Children and adolescents with ADHD
Summary of findings table ‐ PUFA may leads to higher ADHD symptoms – improvement – medium term compared with placebo (low certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – inattention, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
Side effects – overall · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in side effects – overall compared with placebo (moderate certainty).
1 finding from 1 review
Loss to · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in loss to compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in mean change in visual acuity at 1 year (number of letters) compared with ranibizumab (high certainty).
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate